Medicaid supplemental rebate agreement

CELLTRION USA INC has been awarded a contract (X043675) by the New York Department of Health effective July 1, 2026, through June 30, 2029. The three-year contract term reflects a comprehensive service or product delivery engagement, though specific details regarding the nature of goods or services to be provided are not detailed in the available award documentation. The contracting organization's health department focus suggests the engagement likely involves pharmaceutical, biotechnological, or healthcare-related products or services, consistent with CELLTRION USA INC's corporate profile as a biopharmaceutical manufacturer.

The contract carries a cumulative value of $0.00 as currently recorded, indicating either that the valuation data has not been finalized in the award documentation or that this represents a requirements-based or time-and-materials contract structure with value to be determined through actual utilization. Performance locations and specific annual or total contract values are not identified in the provided award materials. Prospective parties seeking detailed contract specifications, performance requirements, or financial terms should consult the complete contract documentation filed with the New York Department of Health.